Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
29 janv. 2024 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
29 janv. 2024 06h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Behavioral Health Market revenue to surpass USD 67 Billion by 2033, says Research Nester
22 janv. 2024 05h00 HE
|
Research Nester
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global behavioral health market size is projected to expand at ~5% CAGR between 2023 and 2033. The market is expected to garner a revenue of USD 67...
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
18 janv. 2024 00h21 HE
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
UK’s Psychiatrist-Led Diverse Diagnostics Offers Private ADHD Assessment with Free Consultations
12 janv. 2024 09h00 HE
|
Diverse Diagnostics
Glasgow, United Kingdom, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Diverse Diagnostics, a leading psychiatric clinic based in the United Kingdom, announces the launch of its specialised service offering...
Done. Reaches Milestone in Opening 30 Physical Clinic Locations
04 déc. 2023 09h00 HE
|
Done.
San Francisco, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Done., a patient-first startup established by a team of experts dedicated to supporting the millions of adults facing the ADHD and mental health...
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
13 nov. 2023 16h15 HE
|
Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...
Cingulate to Host CNS Key Opinion Leader Panel in New York City
17 oct. 2023 14h22 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
03 oct. 2023 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
Cingulate Inc. to Present at the LD Micro Main Event XVI
21 sept. 2023 13h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...